Santen & UBE Receives the US FDA’s Approval of Omlonti for the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension
Shots:
- The approval was based on 3 clinical trials evaluating Omlonti (0.002%) in open-angle glaucoma or ocular hypertension patients with baseline IOP of ~24-26mm Hg for a duration of 3mos. The 3rd study included a 9mos. open-label treatment period following a 3mos. double-masked treatment period
- The results from the study indicated an IOP reduction for all the treatment arms incl. a reduction of IOP in the Omlonti arm from 5-7mm Hg across all 3 studies along with a reduction in timolol & latanoprost arm were 5-7 & 6-8mm Hg
- Omlonti is a relatively selective EP2 receptor agonist that reduces the elevated IOP by increasing aqueous humor drainage through the conventional/trabecular & uveoscleral outflow pathways
Ref: Buisnesswire | Image: Santen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
